Figure 1.

The anti-4-1BB and anti-PD-1 combination therapy suppresses AML tumor growth and enhances mouse survival.. AML-ETO9a tumor-bearing mice were treated with anti-4-1BB, anti-PD-1 or their combination. Individual tumor growth curves from untreated or anti-4-1BB treated mice (A), the percentage of PD-1 expressing CD8 + T cells (B), PD-L1 expression on tumor cells (C), and monocytes (D) is shown. Tumor growth curves from mice treated with anti-PD-1 or in combination with anti-4-1BB (E) is plotted, in addition to summary data at day 36 (F), survival curves (G) and the fraction of NK cells (H) and CD8 + T cells (I) grouped into responders (tumor free) and non-responders. The data is presented as individual mice or mean ± SEM (n = 3 to 7) and was analyzed by student t-test, or Two-way ANOVA followed by Tukey’s post-hoc test to determine the significance (p < 0.05). Survival curves were analysed by the Mantel-Cox log-rank multiple comparison test. * p < 0.05, ** p < 0.01, *** p < 0.001.